GHK-Cu reduces inflammatory cytokines and oxidative stress markers that contribute to premature aging
Only Elamipretide and Bremelanotide are FDA approved with full safety data
Here is a breakdown of the major categories: Growth Hormone Secretagogues CJC-1295 : studied for its role in stimulating growth hormone release Ipamorelin : a selective growth hormone secretagogue GHRP-2 and GHRP-6 : growth hormone-releasing peptides used in receptor binding research MK-677 (Ibutamoren) : a non-peptide GH secretagogue with a long half-life Tissue Repair & Cytoprotective Peptides BPC-157 (Body Protection Compound-157) : among the most studied peptides in preclinical research, with a substantial literature base in wound healing and gastrointestinal cytoprotection models TB-500 (Thymosin Beta-4) : investigated for its role in tissue remodeling and angiogenesis in preclinical settings GHK-Cu : a copper-binding tripeptide with active research into dermal repair and cytoprotective mechanisms GLP-1 & Metabolic Compounds PureRawz has expanded into GLP-1 receptor agonist research, offering: Semaglutide : a GLP-1 receptor agonist studied for metabolic pathway modulation Tirzepatide : a dual GIP/GLP-1 receptor agonist with active research in metabolic regulation Retatrutide : a triple agonist (GIP, GLP-1, glucagon) under investigation in early-phase metabolic research SARMs RAD-140 (Testolone) : a selective androgen receptor modulator studied for anabolic effects in preclinical models LGD-4033 (Ligandrol) : investigated for muscle tissue selectivity and androgen receptor binding Ostarine (MK-2866) : among the most widely researched SARMs for muscle preservation models Cardarine (GW-501516) : a PPAR-delta agonist studied for metabolic and endurance-related pathways Nootropics PureRawz carries over 66 nootropic research compounds across multiple formats, including Phenibut HCL, Noopept, and Aniracetam
The formation of abnormal synovial cysts in connection with the joints
A product can also be medicinal where it is intended to restore, correct or modify physiological functions through pharmacological, immunological or metabolic action
In the S-1, Netskope disclosed that one of their channel partners accounted for 12% of their revenue in fiscal year 2025
